$MET

METLIFE INC

1
0
0

No SEC Form 4 filings for $MET in the last 30 days.

See all $MET insider activity →

Ukraine antitrust body clears MetLife's acquisition of Polish PZU unit

Ukraine's Antimonopoly Committee approved PZU's acquisition of MetLife's Ukrainian unit, subject to non-compete clauses. PZU aims to close the deal by early 2027, pending NBU approval. The transaction aligns with PZU's regional expansion strategy. MetLife PJSC leads Ukraine's life insurance market with UAH 1.599 billion in H1 2026 premiums, up 11.4% YoY.

MET sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning MET (METLIFE INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent MET coverage spans financial news, market movers and mergers & acquisitions.

What's driving MET

AlphAI scores every news story that mentions MET with an AI model for sentiment and relevance, and aggregates insider trades from METLIFE INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MET

Score
$METMedAI 8/10

Ukraine antitrust body clears MetLife's acquisition of Polish PZU unit

Ukraine's Antimonopoly Committee approved PZU's acquisition of MetLife's Ukrainian unit, subject to non-compete clauses. PZU aims to close the deal by early 2027, pending NBU approval. The transaction aligns with PZU's regional expansion strategy. MetLife PJSC leads Ukraine's life insurance market with UAH 1.599 billion in H1 2026 premiums, up 11.4% YoY.

Michael Burry raises a strong warning about the private markets

Michael Burry warns of potential trouble in private-market credit, citing valuation concerns and insurer exposure. He notes rising interest rates could pressure AI infrastructure projects. Burry has taken bearish positions in MetLife and AI-related stocks. Private credit funds have seen increased withdrawal requests and reduced lending, with potential defaults projected at 8%. Insurers hold significant private credit, and AI-related lending has surged.

MET Maintained by UBS -- Price Target Raised to $110

UBS maintained a 'Buy' rating on MetLife (MET) and raised its price target to $110 from $105. MetLife's stock is currently trading at $98.61, which is 4.3% above its GF Value™ of $94.58. The company has a GF Score™ of 76/100, indicating solid performance in profitability and momentum. MetLife operates in various segments, including insurance and investment management, with a market capitalization of approximately $62.66 billion.

$METLow

The benefits confusion gap is costing your employees, says MetLife

MetLife's 2026 U.S. Employee Benefit Trends Study found 83% of employees stress over rising living and medical costs, with financial confidence at its lowest since 2012. MetLife's Ramy Tadros argues a 'confusion gap' leads to underinsurance. The company is deploying AI-driven enrollment guidance to help employees select benefits, aiming to improve protection and ROI for employers. Tadros urges HR leaders to demand more data-driven insights from brokers and invest in closing the confusion gap.

Michael Burry Warns of Risks for These Stocks

Michael Burry adjusted his portfolio, identifying Deckers Outdoor (DECK), lululemon (LULU), Fannie Mae (FNMA), Freddie Mac (FMCC), Fiserv (FISV), Sprouts Farmers Market (SFM), Zoetis (ZTS), and MetLife (MET) as vulnerable to tax-loss selling. He swapped DECK for LULU, FMCC for FNMA, and shifted SFM and ZTS into long-term call options. Burry also added put options on MET, citing risks in private credit and equity valuations.

Related tickers